

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

Assignment ID: TMI89437

|   |  |                       |                       |
|---|--|-----------------------|-----------------------|
| <b>SUBMISSION TYPE:</b>   | NEW ASSIGNMENT                             |                       |                       |
| <b>NATURE OF CONVEYANCE:</b>  | SECURITY INTEREST                          |                       |                       |
| <b>CONVEYING PARTY DATA</b>   |  |                       |                       |
| <b>Name</b>   | <b>Formerly</b>                            | <b>Execution Date</b> | <b>Entity Type</b>    |
| Alcresta Therapeutics, Inc.   |  | 03/12/2024            | Corporation: DELAWARE |
| <b>RECEIVING PARTY DATA</b>   |  |                       |                       |
| <b>Company Name:</b>  | Twin Brook Capital Partners, LLC, as Agent |                       |                       |
| <b>Street Address:</b>  | 111 South Wacker Drive, 36th Floor         |                       |                       |
| <b>City:</b>  | Chicago                                    |                       |                       |
| <b>State/Country:</b>   | ILLINOIS                                   |                       |                       |
| <b>Postal Code:</b>   | 60606                                      |                       |                       |
| <b>Entity Type:</b>   | Limited Liability Company: DELAWARE        |                       |                       |
| <b>PROPERTY NUMBERS Total: 5</b>  |  |                       |                       |
| <b>Property Type</b>  | <b>Number</b>                              | <b>Word Mark</b>      |                       |
| <b>Serial Number:</b>   | 87066536                                   | ALCRESTA THERAPEUTICS |                       |
| <b>Serial Number:</b>   | 86698947                                   |                       |                       |
| <b>Serial Number:</b>   | 86690981                                   | RELIZORB              |                       |
| <b>Serial Number:</b>   | 85829579                                   | ILIPASE               |                       |
| <b>Serial Number:</b>   | 85554028                                   | ALCRESTA              |                       |
| <b>CORRESPONDENCE DATA</b>  |  |                       |                       |
| <b>Fax Number:</b>  | 3129021061                                 |                       |                       |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> |  |                       |                       |
| <b>Phone:</b>   | 3125778438                                 |                       |                       |
| <b>Email:</b>   | raquel.haleem@katten.com                   |                       |                       |
| <b>Correspondent Name:</b>  | Raquel Haleem c/o Katten Muchin            |                       |                       |
| <b>Address Line 1:</b>  | 525 West Monroe Street                     |                       |                       |
| <b>Address Line 4:</b>  | Chicago, ILLINOIS 60661                    |                       |                       |
| <b>NAME OF SUBMITTER:</b>   | Raquel Haleem                              |                       |                       |
| <b>SIGNATURE:</b>   | Raquel Haleem                              |                       |                       |
| <b>DATE SIGNED:</b>   | 03/12/2024                                 |                       |                       |
| <b>Total Attachments: 5</b>   |  |                       |                       |
| source=twin brook alcresta trademark security agreement draft 2024(300567100.3)#page1.tif   |  |                       |                       |

CH \$140.00.00 87066536

source=twin brook alcresta trademark security agreement draft 2024(300567100.3)#page2.tif

source=twin brook alcresta trademark security agreement draft 2024(300567100.3)#page3.tif

source=twin brook alcresta trademark security agreement draft 2024(300567100.3)#page4.tif

source=twin brook alcresta trademark security agreement draft 2024(300567100.3)#page5.tif

**TRADEMARK SECURITY AGREEMENT**

THIS TRADEMARK SECURITY AGREEMENT (this “**Agreement**”) is made as of March 12, 2024, by ALCRESTA THERAPEUTICS, INC., a Delaware corporation (“**Grantor**”), in favor of TWIN BROOK CAPITAL PARTNERS, LLC, in its capacity as Agent for the Lenders (as defined in the Credit Agreement referenced below) (in such capacity, “**Grantee**”):

**W I T N E S S E T H**

WHEREAS, Grantor, the other Loan Parties party thereto, the financial institutions party thereto from time to time as Lenders, and Grantee have entered into that certain Credit Agreement, dated as of the date hereof (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “**Credit Agreement**”), pursuant to which Grantee and Lenders have agreed, subject to the terms and conditions thereof, to make certain loans to, and other credit accommodations in favor of, Borrowers (collectively, the “**Loans**”).

WHEREAS, pursuant to the terms of that certain Guarantee and Collateral Agreement, dated as of the date hereof, among Grantee, Grantor, and the other Loan Parties (as the same may be amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “**Guarantee and Collateral Agreement**”), Grantor has granted to Grantee, for its benefit and the benefit of Lenders, a security interest and lien upon substantially all assets of Grantor, including all right, title and interest of Grantor in, to and under all now owned and hereafter acquired Trademarks (as defined in the Guarantee and Collateral Agreement, including registrations and applications therefor), together with the goodwill of the business symbolized by Grantor’s Trademarks, and all products and proceeds thereof, to secure the payment of all amounts owing by Borrowers under the Credit Agreement.

NOW, THEREFORE, in consideration of the premises set forth herein and for other good and valuable consideration, receipt and sufficiency of which are hereby acknowledged, Grantor agrees as follows:

1. Incorporation of Representations and Warranties of the Credit Agreement and Guarantee and Collateral Agreement. The representations and warranties contained in the Credit Agreement and the Guarantee and Collateral Agreement to the extent applicable to Grantor are hereby incorporated herein in their entirety by this reference thereto. All capitalized terms used herein but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Guarantee and Collateral Agreement. If there is a conflict between the Guarantee and Collateral Agreement and this Agreement, the terms of the Guarantee and Collateral Agreement shall control.

2. Grant and Reaffirmation of Grant of Security Interests. To secure the payment and performance of the Obligations (as defined in the Credit Agreement), Grantor hereby grants to Grantee, for its benefit and the benefit of Lenders, and hereby reaffirms its prior grant pursuant to the Guarantee and Collateral Agreement of, a continuing security interest in Grantor’s entire right, title and interest in and to the following (all of the following items or types

of property being herein collectively referred to as the “**Trademark Collateral**”), whether now owned or existing or hereafter created, acquired or arising:

(i) each Trademark listed on Schedule A annexed hereto, together with any reissues, continuations or extensions thereof, and all of the goodwill of the business connected with the use of, and symbolized by, each such Trademark; and

(ii) all products and proceeds of the foregoing, including without limitation, any claim by Grantor against third parties for past, present or future (a) infringement or dilution of each such Trademark, or (b) injury to the goodwill associated with each such Trademark.

3. Intent-To-Use Trademarks. Notwithstanding the foregoing, and solely to the extent, if any, that, and solely during the period, if any, in which the grant of a security interest therein would impair the validity or enforceability of any registration that issues from such intent-to-use application under applicable federal law, the Trademark Collateral shall not include any intent-to-use United States Trademark applications for which an amendment to allege use or statement of use has not been filed under 15 U.S.C. § 1051(c) or 15 U.S.C. § 1051(d), respectively, or if filed, has not been deemed in conformance with 15 U.S.C. § 1051(a) or examined and accepted, respectively, by the United States Patent and Trademark Office, provided that upon such filing and acceptance, such intent-to-use applications shall be included in the Trademark Collateral and automatically subject to the security interest granted herein.

4. Governing Law. THIS AGREEMENT SHALL BE A CONTRACT MADE UNDER AND GOVERNED BY THE INTERNAL LAWS OF THE STATE OF NEW YORK APPLICABLE TO CONTRACTS MADE AND TO BE PERFORMED ENTIRELY WITHIN SUCH STATE, WITHOUT REGARD TO CONFLICT OF LAWS PRINCIPLES.

**- Remainder of Page Intentionally Left Blank; Signature Page Follows -**

IN WITNESS WHEREOF, Grantor has duly executed this Agreement as of the date first written above.

**ALCRESTA THERAPEUTICS, INC.,**  
a Delaware corporation

By:                     Daniel Orlando                      
Name: Daniel Orlando  
Title: Chief Executive Officer

Trademark Security Agreement

**TRADEMARK**  
**REEL: 008367 FRAME: 0007**

Agreed and Accepted  
As of the Date First Written Above:

**TWIN BROOK CAPITAL PARTNERS, LLC,**  
as Agent

By:   
Name: Kim Trick  
Title: Managing Director

**Schedule A**

| <b>Mark</b>           | <b>Application No.</b> | <b>Application Date</b> | <b>Registration No.</b> | <b>Registration Date</b> |
|-----------------------|------------------------|-------------------------|-------------------------|--------------------------|
| ALCRESTA THERAPEUTICS | 87066536               | 09-JUN-2016             | 5387508                 | 23-JAN-2018              |
| Design Only           | 86698947               | 20-JUL-2015             | 5167228                 | 21-MAR-2017              |
| RELIZORB              | 86690981               | 13-JUL-2015             | 5087672                 | 22-NOV-2016              |
| ILIPASE               | 85829579               | 22-JAN-2013             | 5355288                 | 12-DEC-2017              |
| ALCRESTA              | 85554028               | 27-FEB-2012             | 4973360                 | 07-JUN-2016              |